The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

US stocks opened higher Tuesday amid strong corporate earnings, upcoming Fed rate decision, and anticipation around major ...

Shares in the $247 bln obesity drugmaker fell over 20% after it said sales would grow more slowly than expected. Competition ...

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%. The maker ...

Novo Nordisk announced that Mike Doustdar has been appointed as the new CEO on Tuesday. Photo by Ida MArie Odgaard/EPA-EFE.

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...